Terminated PHASE1 INTERVENTIONAL 2-arm NCT04175132

Binding of Foliglurax to Regions in the Brain in Healthy Participants and in Patients With Parkinson's Disease (PD)

Interventional, Open-label, Positron Emission Tomography (PET) Study With [11C]-PXT012253 Investigating the Brain mGlu4 Receptor Occupancy, Safety, Tolerability and Pharmacokinetics of Foliglurax in Healthy Subjects and Patients With Parkinson's Disease

Sponsor: H. Lundbeck A/S

Conditions Healthy Parkinson Disease

Interventions foliglurax

Updated 5 times since 2019 Last updated: Dec 8, 2020 Started: Nov 12, 2019 Primary completion: Mar 3, 2020 Completion: Mar 10, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

New efficacy data from another study

Other terminated trials from H. Lundbeck A/S

See all terminations from H. Lundbeck A/S

Other Healthy trials with similar outcome

Browse all Healthy trials

Listed as NCT04175132, this PHASE1 trial focuses on Healthy and Parkinson Disease and remains terminated or withdrawn. Sponsored by H. Lundbeck A/S, it has been updated 5 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jul 2020 — Jan 2021 [monthly]

Terminated PHASE1

Status: Recruiting → Terminated
Dec 2019 — Jul 2020 [monthly]

Recruiting PHASE1

First recorded

Nov 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

H. Lundbeck A/S

Data source: H. Lundbeck A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stockholm, Sweden